The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I would also like to add my thanks to you, Ehsan, for the informative post.
I agree that now is the time for patience.
Thanks Ehsan, always appreciate the informative posts!
I agree, with time we will all be rewarded. The more I hear and read about this company the more bullish i get.
@Irontaz
Thanks, buddy.
I just want the people to know, This company is in the right direction and would make money for everyone who invests here. Short or long-term. we all just need to be patient and give it some more time.
Ehsan, top work again fella, I can see how much of a passion you have for this company. Happy Investing.
1. The 2021 half-year represented a strategically important period for the Group and thus far MGC Pharma has delivered significant progress on an upward growth trajectory as it delivers on its growth strategy.
2. The Group delivered total sales for the half-year of $741,911 in pharma revenue (2019: $134,536).
3. First shipment of MP Line products directly to patients in Brazil. MGC Pharma is the first company globally to ship high THC formulations directly to a patient's door in Brazil
4. $5 million cash grant to establish ArtemiCTM production in Malta. Construction of new facility commenced during the December quarter and will be completed in mid-2021
5. Launch of CannEpilĀ® App
6. Completion of Phase II clinical trial on COVID-19 patients.
The trial met all the FDA requirements for a COVID-19 study including population diversity (age, medical history, and genetic diversity), and demonstrated a full safety profile with no drug-related adverse events.
7. Further successful results from pre-clinical glioblastoma research.
Results from the ongoing pre-clinical research program focused on evaluating cannabinoid formulations in the development of a treatment of the most aggressive and therapeutically resistant brain tumour, glioblastoma, have shown further successful results.
If successful, this would potentially lead to a significant breakthrough in the treatment of brain cancer through oral administration (rather than invasive treatments).
8. Binding term sheet signed for the import and sales of CannEpilĀ® in Israel.
MGC Pharma executed a binding term sheet with IM Cannabis Corp. (IMC), one of the leading cannabis companies in Israel with operations in Europe, for the exclusive wholesale import, sales, and distribution of CannEpilĀ® in Israel.
In Europe, IMC has established a medical cannabis operation first with its distribution subsidiary in Germany and augmented by strategic agreements with EU-GMP standard certified suppliers.
9. $15M Finance Facility
In September 2020, a convertible securities financing agreement was signed with Mercer Street Global Opportunity Fund, LLC ("Mercer"), to provide the Group with funding of up to a total of $15 million.
10. Following the London Stock Exchange listing and associated share placement, the Group is in a strong financial position to pursue identified growth initiatives.
11. With the successful results of phase II clinical trials on ArtemiCTM, a phase III trial is planned to commence in the June quarter.
If you think I miss something, feel free to share it under here.